Sociodemographic and psychological variables influencing adherence to antiretroviral therapy

AIDS

Volumn 13, Issue 13, 1999, Pages 1763-1769

  Gordillo, Victoria ^a,d   Del Amo, Julia ^b   Soriano, Vicente ^a   González Lahoz, Juan ^c  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b Research Unit   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d NONE   (Spain)

Author keywords

Adherence; Antiretroviral treatment; Compliance; Depression; Psychological factors

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN;

ADULT; AGE; ARTICLE; DEMOGRAPHY; DEPRESSION; EDUCATION; EMPLOYMENT; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; SELF REPORT; SOCIAL ASPECT; SOCIAL SUPPORT;

ADULT; ANTI-HIV AGENTS; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; PATIENT COMPLIANCE; QUESTIONNAIRES; RISK FACTORS; SOCIOECONOMIC FACTORS; SPAIN;

EID: 0033391009     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199909100-00021     Document Type: Article

References (45)

1. Palella F, Delaney K, Moorman A, et al. Declining morbidity and mortality among patients with advanced HIV infection. N Engl J Med 1998, 338:853-860.
2. Lange J. Issues for the future of antiretroviral therapy. Antiviral Ther 1997, 2 (suppl. 4):71-83.
3. Williams A, Friedland G. Adherence, compliance, and HAART. AIDS Clin Care 1997, 7:51-58.
4. Veenstra J, Schuurman R, Cornelissen M, et al. Transmission of zidovudine-resistant HIV-1 following deliberate injection of blood from a patient with AIDS: characteristics and natural history of the virus. Clin Infect Dis 1995, 21:556-560.
5. Imrie A, Beveridge A, Genn W, Vizzard J, Cooper D. Transmission of HIV-1 resistant to nevirapine and zidovudine: Sydney Primary HIV Infection Study Group. J Infect Dis 1997, 175:1502-1506.
6. Hecht F, Grant R, Petropoulos C, et al. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med 1998, 339:307-311.
7. Erwin J. Adherence and its implications for antiretroviral therapy. Int Antiviral News 1998, 6: 12-14.
8. Rodriguez-Rosado R, Jiménez-Nácher I, Soriano V, Antón P, González-Lahoz J. Virological failure and adherence to antiretroviral therapy in HIV-infected patients [letter]. AIDS 1998, 12:1112-1113.
9. Piñeiro F, Gil V, Donis M, et al. Usefulness of six indirect methods to evaluate drug therapy compliance in non-insulin-dependent diabetes mellitus. Rev Clin Esp 1997, 197:555-559.
10. Singh N, Squier C, Sivek C, et al. Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: prospective assessment with implications for enhancing compliance. AIDS Care 1996, 8:261-269.
11. Rabkin J, Ferrando S, A "second life" agenda. Psychiatric research issues raised by protease inhibitor treatments for people with the human immunodeficiency virus or the acquired immunodeficiency syndrome. Arch Gen Psychiatry 1997, 54:1049-1053.
12. Mehta S, Moore RD, Graham NM. Potential factors affecting adherence with HIV therapy. AIDS 1997, 11:1665-1670.
13. Besch C. Compliance in clinical trials. AIDS 1995, 9:1-10.
14. Caraël M, Coates TJ. Social, cultural and political aspects. AIDS 1996, 10(suppl A):S181-S182.
15. Conde Y, Useros S. Adaptación castellana de la escala de evaluación conductual para la depresión de Beck. Rov Psicol y Psiq Méd 1975, 4: 217-236.
16. Hamilton M. The assessment of anxiety states by raring, Brit J Med Psychol 1959, 32: 50-55,
17. Jong MD, De Boer RJ, De Wolf F, et al. Overshoot of HIV-1 viraemia after early discontinuation of antiretroviral treatment. AIDS 1997, 11:F79-F84.
18. Fätkenheuer G, Theisen A, Rockstroh I, et al. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS 1997, 11: F113-F116.
19. Montaner J, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients. JAMA 1998, 279:930-937.
20. Carpenter C, Fischl M, Hammer S, et al. Antiretroviral therapy for HIV infection in 1997. JAMA 1997, 277:1962-1969.
21. Leserman J, Pelitto JM, Perkins D, et al. Severe stress, depressive symptoms, and changes in lymphocyte subsets in human immunodeficiency virus-infected men, A 2-year follow-up study. Arch Gen Psychiatry 1997, 54: 279-285.
22. Judd F, Mijch A. Depressive symptoms in patients with HIV infection. Aust NZ J Psychiatry 1996, 30:104-109.
23. Perry S, Fishman B, Jacobsberg L, et al. Relationships over 1 year between lymphocyte subsets and psychosocial variables among adults with infection by human immunodeficiency virus. Arch Gen Psychiatry 1992, 49: 396.
24. Perry SW, Jacobsberg IB, Fishman B, et al. Psychological responses to serological testing for HIV. AIDS 1990, 4:145-152.
25. Kern D, Collins M, Fultz T, et al. An enhanced-sensitivity branched-DNA assay for quantification of HIV-1 RNA in plasma. J Clin Microbiol 1996, 34:3196-3202.
26. Eldred L, Albert W, Chaisson R, Moore R. Adherence to antirretroviral drugs and pneumocystis prophylaxis in HIV disease. J Acquir Immune Defic Syndr Hum Retrovirol 1998, 18:117-125.
27. Knobel H, Serrano C, Hernandez P, Pavesi M, Diez A. Acceptance, adherence and tolerance of antiretroviral therapy in HIV-infected patients. An Med Intern (Madrid) 1997, 14:445-449.
28. Ickovics JR. Measures of adherence. Adherence to New HIV Therapies: A Research Conference. Washington, DC. November 1997.
29. Norell S. Accuracy of patient interviews and estimates by clinical staff in determining medication compliance. Soc Sci Med 1981, 15:57-61.
30. Ferrando S, Wall T, Batki S, et al. Psychiatric morbidity, illicit drug use and adherence to zidovudine among injection drug users with HIV disease. Am J Drug Alcohol Abuse 1996, 22:475-487.
31. Gerbert B, Maguire BT, Bleeker T, et al. Primary care physicians and AIDS: attitudinal and structural barriers to care. JAMA 1991, 266:2837-2842.
32. Fedder D. Drug use in the elderly: issues of non-compliance. Drug Intell Clin Pharm 1984, 18:158-162.
33. Lipsitz J, Williams J, Rabkin J, et al. Psychopathology in male and female intravenous drug users with and without HIV infection. Am J Psychiatry 1994, 151:1662-1668.
34. Zorrilla E, McKay J, Luborsky I, Schmidt K. Relation of stressors and depressive symptoms to clinical progression of viral illness. Am J Psychiatry 1996 153:626-635.
35. Lyketsos C, Hoover D, Guccione M, et al. Depressive symptoms as predictors of medical outcomes of HIV infection: Multicenter AIDS cohort study. JAMA 1993, 270:2563-2567.
36. Burack J, Barrett D, Stall R, et al. Depressive symptoms and CD4 lymphocyte decline among HIV-infected men. JAMA 1993, 270:2563-2567.
37. Markowilz JC, Rabkin JG, Perry SW. Treating depression in HIV-positive patients. AIDS 1994, 8:403-412.
38. Mayne I, Vittinghoff E, Chesney M, et al. Depressive affect and survival among gay and bisexual men infected with HIV. Arch Gen Psychiatry 1996, 156:2233-2238.
39. Ohmit S, Schuman P, Schoenbaum E, et al. Adherence to antiretroviral therapy (ART) among women in the HIV Epidemiology Research Study (HERS) and Women's Inter-Agency HIV Study (WIHS). 12th World AIDS Conference, Geneva, Switzerland, 1998 [Abstract 32347].
40. Lyketsos C, Hoover D, Guccione M, et al. Changes in depressive symptoms as AIDS develops. Am J Psychiatry 1996, 153:1430-1437.
41. Auerbach J. The role of behavioral research in HIV/AIDS prevention. Curr Op Infect Dis 1998, 11:3-7.
42. Sweeney K, McAuley D, Pereira D. Personal significance: the third dimension. Lancet 1998, 351:134-136.
43. Anonymous. AIDS Surveillance in Madrid. Boletin Epidemiológico de la Comunidad de Madrid, 1997, July: 5.
44. Chesney M. New Antiretroviral therapies: adherence challenges and strategies. Antiviral Academy Meeting. Mont lremblant, Canada, March 1998.
45. Duffy D. Dialogue: the core clinical skill. Ann Intern Med 1998, 128:139-141.